Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | CHEK2 |
| Variant | G151S |
| Impact List | missense |
| Protein Effect | unknown |
| Gene Variant Descriptions | CHEK2 G151S lies within the FHA domain of the Chek2 protein (UniProt.org). G151S complements Rad53 loss similar to wild-type in a yeast high-throughput assay (PMID: 39146382), but has not been fully biochemically characterized and therefore, its effect on Chek2 protein function is unknown. |
| Associated Drug Resistance | |
| Category Variants Paths |
CHEK2 mutant CHEK2 G151S |
| Transcript | NM_007194.4 |
| gDNA | chr22:g.28725118C>T |
| cDNA | c.451G>A |
| Protein | p.G151S |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_145862.2 | chr22:g.28725118C>T | c.451G>A | p.G151S | RefSeq | GRCh38/hg38 |
| NM_007194.4 | chr22:g.28725118C>T | c.451G>A | p.G151S | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CHEK2 G151S | prostate cancer | sensitive | Enzalutamide + Talazoparib | FDA approved - On Companion Diagnostic | Actionable | In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including CHEK2 G151S (PMID: 42223064; NCT04821622). | detail... detail... 42223064 |